GlaxoSmithKline plc (ADR) (GSK), Sarepta Therapeutics Inc (SRPT): The Good and Bad of a Competitor’s Failure

Page 1 of 2

GlaxoSmithKline plc (ADR) (NYSE:GSK)On the surface, GlaxoSmithKline plc (ADR) (NYSE:GSK)‘s release of phase 2 data on drisapersen looks like good news for Sarepta Therapeutics Inc (NASDAQ:SRPT)‘s competing Duchenne Muscular Dystrophy drug, eteplirsen.

Investors seem to think so; shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) were up almost 3.3% Friday, while Prosensa, which developed drisapersen and licensed it to GlaxoSmithKline plc (ADR) (NYSE:GSK), was down 8%.

But be careful though. Sometimes, one man’s trash is just another man’s trash.

First, the blah data
Keep in mind this is phase 2 data. GlaxoSmithKline plc (ADR) (NYSE:GSK) is already running a phase 3 trial that should read out later this year. The phase 2 data will have little influence on the approvability of drisapersen, but it could give hints as to whether the phase 3 trial will be successful and how it might compete with Sarepta Therapeutics Inc (NASDAQ:SRPT)’s eteplirsen.

The study looked at both continuous dosing of drisapersen, defined as once weekly, and intermittent dosing, which consisted of alternating between once and twice a week for six weeks and then taking the seventh to 10th weeks off before restarting the cycle.

The continuous dosing clearly worked better after 25 weeks on the drug, with 72% of patients showing an increase in dystrophin, the protein missing in Duchenne muscular dystrophy patients that leads to muscle wasting. The intermittent dosing produced increases in dystrophin levels in 59% of patients. Only one out of 18 of the patients treated with placebo registered positive, so drisapersen is clearly doing something.

The problem for Galxo and Prosensa is Sarepta Therapeutics Inc (NASDAQ:SRPT)’s data indicate that all of patients taking eteplirsen had an increase in dystrophin levels. One hundred percent trumps 72%, although the two companies measured dystrophin levels in different ways, and it isn’t clear which one is more stringent.

Be careful
In addition to the apples-to-oranges comparison across clinical trials, there’s the issue of using dystrophin as an endpoint for approval. Sarepta Therapeutics Inc (NASDAQ:SRPT) has two options for approval using its phase 2 data. It could gain accelerated approval based on the surrogate endpoint of increasing dystrophin or the Food and Drug Administration could award full approval based on the boys taking eteplirsen walking further, a clinically meaningful endpoint.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 44 percentage points in 21 months Learn how!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!